Completed Trials
CYTOFLOC: Cytosponge™ for post‐chemoradiation surveillance of oesophageal cancer
CYTOFLOC: Cytosponge™ for post‐chemoradiation surveillance of oesophageal cancer
FRONTIER: Fluciclovine (18F) imaging of breast cancer
FRONTIER: An open-labelled study to characterise Fluciclovine (18F) uptake measured by positron emission tomography in breast cancer
TARDOX: Targeted chemotherapy using focused ultrasound for liver tumours
TARDOX :A Proof of Concept Study to Investigate the Feasibility of Targeted Release of Doxorubicin from Lyso-thermosensitive Liposomal (LTSL) Doxorubicin (ThermoDox®) Using Focused Ultrasound in Patients with Primary or Secondary Liver Tumours
CAMELLIA: Anti-CD47 antibody terapy in relapsed/refractory Haematological Malignancies
CAMELLIA: A Phase I dose escalation trial of the Humanized Anti-CD47 Monoclonal Antibody Hu5F9-G4 in Acute Myeloid Leukaemia
ATOM: Atovaquone as Tumour HypOxia Modifier
ATOM: Pre-operative window of opportunity study of the effects of atovaquone on hypoxia in non-small cell lung carcinoma.
6MP: A Phase II Clinical Trial in Patients with BRCA Defective Tumours
6MP: Phase II Clinical Trial Of 6-Mercaptopurine (6MP) And Low-Dose Methotrexate in Patients with known BRCA Defective Tumours
AspECT: A Phase III, Randomised, study of Aspirin and Esomeprazole Chemoprevention in Barrett’s Metaplasia
AspECT: A Phase III, Randomised, study of Aspirin and Esomeprazole Chemoprevention in Barrett’s Metaplasia
BKM120: Palliative thoracic radiotherapy plus BKM120
BKM120: A phase I dose escalation study of the PI3K inhibitor BKM120, given concomitantly with palliative radiotherapy for the treatment of Non-Small Cell Lung Cancer (NSCLC).
CHOP-OR: Study of CHOP with Ofatumumab in Patients with Richter's Syndrome
CHOP-OR: Phase 2 single arm multi-centre feasibility study of CHOP combined with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter's syndrome
COG : Gefitinib for oesophageal cancer progressing after chemotherapy
COG: Randomised Phase 3 trial of gefitnib 500mg once daily versus placebo in oesophageal cancer progressing after chemotherapy